Loading...

ZVRA ZEVRA THERAPEUTICS INC Disposals and divestitures 8-K Filing

ZVR

ZVR

ZEVRA THERAPEUTICS INC

(ZVRA)

2025 8-K

Show Summary

Summary

Financial Statements

Financial Results

Management Change

Q3 Financial Results

Q2 Earnings Release

Underwriting Agreement

Financial Results

FDA Approval for Arimoclomo...

Equity Distribution Agreement

FDA Meeting for Drug Applic...

Clinical Trial Results

Annual Meeting of Stockholders

Clinical Trial Results

Investor Presentation

FDA Review Period Extended ...

Acquisition of Acer Therape...

Appointment of Director

FDA Acknowledges Receipt of...

Agreement, Merger, Offering

Merger Agreement

Appointment of Neil F. McFa...

Merger Announcement

Merger Agreement

Appointment and Resignation

Results of Operations and F...

Resignation of CEO and Dire...

Annual Meeting of Stockholders

Appointment of Wendy L. Dix...

Regulatory Closure of SVB

Proxy Statement Filing

Financial Condition

Annual Meeting Notice

Management Changes

External Links:

On April 1, 2025, Zevra Therapeutics completed the sale of its Rare Pediatric Disease Priority Review Voucher for $150 million, and as of March 31, 2025, reported cash and investments of approximately $68.7 million.

AI Assistant

ZEVRA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.